

Title: Why do primary care physicians not always follow guidelines on statin prescribing for primary prevention?

Authors

Yasmeen Hassan, The University of East Anglia
John Ford, The University of East Anglia
Nicholas Steel, The University of East Anglia
Joanna Sheldon, The University of East Anglia
Robert Fleetcroft, The University of East Anglia

Keywords:

Cardiovascular Diseases, Primary Prevention, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Primary Health Care

Running title; Why do primary care physicians not always follow guidelines on statin prescribing for primary prevention?

Correspondence

Yasmeen Hassan
y.hassan@uea.ac.uk
Norwich Medical School, University of East Anglia, Chancellor Drive, Norwich NR4 7TJ

The material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. The authors declare that there are no conflicts of interest.

Cardiovascular disease (CVD) is a major cause of mortality accounting for 27% of deaths in the United Kingdom (UK) in 2014 and is a great cost to the UK economy, estimated to be £15.2 billion in 2015.[1] Lipid modification is important as there is a positive correlation between the incidence of CVD and cholesterol levels.[2] There is substantial evidence of benefit in prescribing statins to all patients for secondary prevention of CVD and for primary prevention in many of those patients with higher CVD risk.[3] A Cochrane review in 2013 included 18 randomised controlled trials of statin prescribing for primary prevention and reported a reduction in all-cause mortality (OR 0.86, 95% CI 0.79 to 0.94), with the number needed to treat to prevent one death over five years being 96 and an acceptable cost-effectiveness.[3] The Cholesterol Treatment Trialists' Collaboration (CTTC) trial performed a meta-analysis of individual patient data from 27 RCTs and reported in 2012 that statin therapy reduces the risk of major vascular events even in patients with 5 year CVD risks of <5%. [2]

The National Institute for Health and Care Excellence (NICE) guidance recommends the use of the QRISK2 tool to assess CVD risk, and treatment with statins at a >10% ten year risk of developing CVD. This guidance was revised from a >20% risk in 2014 and a >30% risk in 2010.[4] If the current NICE guidance was fully implemented in the UK, it has been estimated that 21% more men aged between 40 and 75 years and 25% more women aged between 55 and 75 years would be receiving statins after ten years of monitoring.[5] Virtually all individuals over 75 years will have a >10% risk of developing CVD in ten years, as the average 10 year risk of CVD without risk factors for males is 25.7%, and for females 19.6%. [6] Despite this evidence base and these guidelines, primary care prescribing rates of statins for primary prevention are lower than predicted.[7] Why might this be?

The causes of variations in the rate of statin prescribing in primary care are multifactorial and influenced by both clinician and patient factors. Qualitative research has identified several factors which include perceived reduced cost-effectiveness, excess workload, patient reluctance to take medication when they are

asymptomatic, potential side effects and medicalisation of healthy individuals.[7] Other research has identified substantive overuse of statins in patients with low CVD risk and conversely underuse in those with high CVD risk and some of these variations are thought to be influenced by single risk factors such as age > 65years, diabetes and hypercholesterolaemia.[8] An understanding of how GPs arrive at a decision to make primary prevention interventions is critical. GPs have reported concern about the clarity of the evidence base and a reluctance to prescribe at lower primary prevention thresholds.[7,8] There is sparse literature regarding the views of GPs and further qualitative work within our department aims to explore this complex issue.

Barriers to prescribing statins for those at lower CVD risk include the transferability of the evidence from research into practice and the potential for side effects, especially diabetes. Regarding the transferability of the evidence, the majority (14/18) of the studies included in the Cochrane review included high risk patients such as those with diabetes, hypercholesterolaemia and hypertension.[3] The CTTC study used a risk scoring system that is not reproducible in primary care patients, unlike QRISK2 or Framingham.[2] The majority of randomised controlled trials using statins are of less than 5 years duration, whereas patients are started on statins with the intention of it being life-long.[2] Regarding the risk of diabetes, the Cochrane review reported an increased relative risk of 1.18 (95% CI 1.01 to 1.39), though only two out of the 18 studies in this meta-analysis reported the risk of new cases of diabetes.[3] A meta-analysis of 17 randomised controlled trials has reported an increased risk of diabetes (odds ratio 1.09 95% CI 1.02-1.17), with no differing treatment effects between statins.[10]

How do we solve this mismatch between the guidelines and evidence base (which support the use of statins in lower risk primary prevention individuals) and prescribing behaviour of GPs, who appear reluctant to prescribe statins for primary prevention to low risk individuals? First, there should be longer-term follow up of participants in existing trials for both adverse and beneficial outcomes, and trial

datasets made available. Second, large randomised controlled trials are needed examining the effectiveness of statins in primary prevention which should be powered to look specifically at side effects. Thirdly, high quality observational data are needed to investigate if the treatment effects of statins reported within the trials are reproducible in a typical low risk primary care population. These suggestions should be complemented by research exploring patient-centred care and shared decision making for asymptomatic patients who are recommended statin therapy. There is some evidence that patients will heed the advice of their doctor [11] and it is therefore essential that doctors have an adequate and transferable evidence base on which to counsel their individual patients. For the moment GPs should continue to have a conversation with patients around the current evidence for statins in primary prevention. After understanding a patient's needs and preferences, the good doctor sets out the evidence in an understandable way and allows the patient to weigh up whether the benefit might outweigh the risk. We acknowledge that trying to provide this detailed and complex information can be challenging for a GP to deliver and certainly challenging for a patient to understand.[12] For a patient with a 10 year risk of >10% for CVD who would respond to quantitative data the above evidence might be communicated in the following way:

“If 96 patients with similar risks to you were to take a statin tablet every day for five years then one life might have been saved.[3] However those patients taking statins are more likely to develop diabetes; if 225 patients took a statin for 4 years then perhaps one might develop diabetes as a side effect;[13] it is possible that this risk of developing diabetes gets higher if you take the statin tablet for a very long time.[14]” Given this evidence, it might not be surprising that many patients may choose not to take statins for primary prevention where benefit appears marginal and there is a risk of diabetes.

A simple one-size fits all approach will not meet the needs of patients and doctors; a process that allows consideration of individual patient characteristics and choices is needed. NICE should provide plain language evidence based statement, such as the

one above, co-produced with patients and the public to facilitate shared decision making. It is unlikely that the NICE guidelines for prescribing statins for primary prevention will be closely adhered to by GPs or accepted by patients until these uncertainties are resolved.

References

1. Townsend N, Bhatnagar P, Wilkins E, Wickramasinghe K, Rayner M: **Cardiovascular Disease Statistics 2015**. London: British Heart Foundation; 2015.
2. Cholesterol Treatment Trialists' (CTT) Collaboration: **The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials**. *The Lancet* 2012, **380**(9841):581-590.
3. Huffman TF, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, Ebrahim S: **Statins for the primary prevention of cardiovascular disease**. *Cochrane Database of Systematic Reviews* 2013(1).
4. NICE: **Cardiovascular disease: risk assessment and reduction, including lipid modification**. *National Institute for Health and Care Excellence* 2014.
5. McFadden E, Stevens R, Glasziou P, Perera R: **Implications of lower risk thresholds for statin treatment in primary prevention: analysis of CPRD and simulation modelling of annual cholesterol monitoring**. *Prev Med* 2015, **70**:14-16.
6. Fleetcroft R, Cookson R: **Do the incentive payments in the new NHS contract for primary care reflect likely population health gains?** *Journal of health services research & policy* 2006, **11**(1):27-31.
7. Kedward J, Dakin L: **A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care**. *British Journal of General Practice* 2003, **53**:684-689.
8. Fairhurst K, Huby G: **From trial data to practical knowledge: Qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia**. *BMJ* 1998, **317**:1130-1134.
9. Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T: **Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study**. *PLoS One* 2013, **8**(7):e67611.
10. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M: **Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials**. *QJM* 2011, **104**(2):109-124.

11. Polak L, Green J: **Using quantitative risk information in decisions about statins: a qualitative study in a community setting.** *Br J Gen Pract* 2015, **65**(633):e264-269.
12. Gale N, Greenfield S, Gill P, Guttridge K, Marshall T: **Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study.** *BMC Family Practice* 2011, **12**:59-69.
13. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJM, Seshasai SRK, McMurray JJ, Freeman DJ, Jukema JW *et al*: **Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.** *The Lancet* 2010, **375**(9716):735-742.
14. Macedo FM, Douglas I, Smeeth L, Forbes H, Ebrahim S: **Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice research datalink.** *BMC Cardiovascular Disorders* 2014, **14**(85).